Motivated by the emerging use of platelet-rich plasma (PRP) for the treatment of tendon-related pathologies, the primary focus of this article is to determine whether human tenocyte behaviour is enhanced when cultured with increasing concentrations of platelet-derived proteins within a derivative of PRP, platelet lysate (PL), enhances tenocyte proliferation and migration in vitro, and whether the mitogenic properties of PL change with donor age.

The present hypothesis is that increasing the platelet-derived protein levels within platelet lysate (PL) promotes tenocyte proliferation and migration in vitro, and that differences may exist between the donor age groups investigated.

There is a clear dose-response relationship between PL concentration and cell behaviour irrespective of PL concentration in PL obtained from young donors.

In contrast, tenocytes displayed similar behaviour irrespective of PL concentration in PL obtained from aged donors.
Strengths and limitations

- This study shows that increasing the platelet-derived protein content from aged donors can have a positive effect on tenocyte behaviour.
- However, it is limited in size and scope, necessitating additional in vivo investigation.

Introduction

Platelet-rich plasma (PRP) is gaining popularity in a variety of clinical settings as an autologous source of bioactive molecules for promoting tissue repair. The supraphysiological concentration of platelet-derived growth factors and cytokines within PRP has been thought to support the regeneration of tendons, the connective tissue structures responsible for anchoring muscle to bone and facilitating mechanical motion.1-3 Ageing tendons have limited healing potential and undergo both cellular and extracellular changes, including reductions in tenocyte proliferation, volume, and metabolic activity, as well as a loss of vascularization, decreased levels of non-collagenous matrix components, and low collagen turnover.1,4 Together, these degenerative tissue changes culminate in diminished strength, increasing the prospect of tendinous injury.4 Pathological tendons may well benefit from the growth factors found in PRP preparations, which have been shown to promote cellular proliferation and support angiogenesis.5 However, the clinical efficacy of PRP for the treatment of tendinopathies has been questioned, as several systematic reviews of the current literature have drawn opposing conclusions.6-10

Reported discrepancies among clinical trials investigating the use of PRP for treating tendinopathies may be attributed in part to inconsistencies in PRP preparation and treatment protocols,8,10 as different methodologies for creating PRP have been reported to affect the kinetics of growth factor release.11 Furthermore, consensus as to how the most elementary of PRP components, platelet concentration, affects tendon healing is lacking. For instance, multiple human studies have reported higher platelet concentrations to have inhibitory effects on cell proliferation in vitro,12-14 whereas others have demonstrated PRP to stimulate tenocyte proliferation in a dose-dependent manner, with platelet concentrations of more than 50 times greater than physiological levels having no inhibitory effects on cell growth.15 Consequently, it is currently unclear if increasing the platelet concentration in PRP is beneficial for treating tendinopathies. Moreover, whether the optimal platelet concentration to promote tendon healing changes with patient age remains to be seen.

In the current study, we cultured human tenocytes within increasing concentrations of platelet lysate (PL), a derivative of PRP, to determine whether higher platelet-derived protein levels enhance cell proliferation and migration in vitro, and whether the mitogenic properties of PL change with donor age. Concentrated PLs, generated from the pooled PRP of both young and aged donors, were combined with cell culture medium using a fixed volumetric ratio to model a range of PRP preparations used clinically. We hypothesized that increasing the platelet-derived protein levels within PL would enhance tenocyte behaviour, and that differences would exist between donor age groups.

Materials and Methods

Preparation of concentrated platelet lysates (PLs). After informed consent was obtained, whole blood from healthy adult donors (n = 14) was collected into a standard blood bag (Teruflex; Terumo BCT, Lakewood, Colorado) or blood tubes (BD Vacutainer; Becton Dickinson, Franklin Lakes, New Jersey) containing anticoagulant citrate dextrose solution A (Baxter Healthcare Corporation, Deerfield, Illinois). Platelet-rich plasma (PRP) was manually separated from other blood components following centrifugation at 200 × g for ten minutes. Care was taken during PRP isolation to avoid disturbing the leucocyte-richuffy coat, thereby minimizing nucleated cell contamination. The leucocyte-poor nature of the PRP isolated when using this methodology was confirmed using a haematological analyzer (Micros 60; Horiha, Irvine, California), with all leucocyte counts falling below the recommended reportable limit (Supplementary Table i). Isolated PRP was subjected to a second round of centrifugation at 2300 × g for ten minutes to form a platelet pellet, and the platelet-poor plasma (PPP) supernatant was completely aspirated. The remaining platelet pellet was resuspended in 1/35 of the initial plasma volume (~70 times over the baseline), resulting in a concentrated PRP solution having about 20 times more platelets than the original PRP (Supplementary Table ii).16 To account for the potential of platelet clumping, platelet counts were obtained manually from the concentrated PRP using a haemocytometer prior to storage at -80°C.17 Upon thawing at 37°C, the PRP preparations were combined into two different pooled platelet products based on an age cut-off of 50 years (Tables I and II), and were subjected to two additional freeze/thaw cycles at -80°C and 37°C to generate concentrated PLs.18 Fragmented platelet bodies were pelleted and removed by centrifugation at 4500 × g for ten minutes, and sodium heparin (Sagent Pharmaceuticals, Inc., Schaumburg, Illinois) was added to the recovered supernatant at 100 IU/ml to prevent hydrogel formation. Finally, the concentrated PLs were serially diluted two-fold in pooled PPP in order to prepare less concentrated forms with 1/2, 1/4, 1/8, and 1/16 of the starting PL volume.

Protein analysis. Quantitative protein analysis was performed using a multiplex, antibody-based assay (Q-Plex Human Angiogenesis; Quansys Biosciences, Logan, Utah) in accordance with the manufacturer’s recommendations.
Platelet counts in concentrated platelet-rich plasma (PRP) from aged donors (> 50 years) prior to lysis

| Age, yrs | Gender | Platelet count, plt/µl | Volume, % |
|----------|--------|------------------------|-----------|
| 51       | Female | 9.8 x 10^4             | 15.4      |
| 53       | Male   | 8.1 x 10^4             | 5.0       |
| 54       | Female | 10.6 x 10^4            | 10.4      |
| 55       | Male   | 8.0 x 10^4             | 23.2      |
| 64       | Female | 9.8 x 10^4             | 7.7       |
| 74       | Female | 7.7 x 10^4             | 6.6       |
| 74       | Female | 11.4 x 10^4            | 6.6       |
| 78       | Female | 6.8 x 10^4             | 25.1      |
| Mean: 63 (sd 11) | Weighted mean: 8.6 x 10^4 | 100 |

Table II. Platelet counts in concentrated platelet-rich plasma (PRP) from young donors (< 50 years) prior to lysis

| Age, yrs | Gender | Platelet count, plt/µl | Volume, % |
|----------|--------|------------------------|-----------|
| 20       | Male   | 11.8 x 10^4            | 5.8       |
| 22       | Female | 9.9 x 10^4             | 19.4      |
| 25       | Male   | 7.2 x 10^4             | 17.5      |
| 30       | Male   | 10.3 x 10^4            | 35        |
| 32       | Male   | 13.9 x 10^4            | 9.7       |
| 33       | Female | 7.7 x 10^4             | 12.6      |
| Mean: 27 (sd 5) | Weighted mean: 9.8 x 10^4 | 100 |

Table III. Simulated clinical platelet-rich plasma (PRP) concentrations

| Experimental condition | Representative clinical PRP concentration |
|------------------------|------------------------------------------|
| Platelet lysate (PL)   | 14x                                      |
| 1/2 PL                 | 7x                                       |
| 1/4 PL                 | 3.5x                                     |
| 1/8 PL                 | 1.75x                                    |
| 1/16 PL                | 0.9x                                     |

Preparation of experimental conditions. Concentrated PLs (PL, 1/2 PL, 1/4 PL, 1/8 PL, and 1/16 PL) were added to culture medium using a fixed volumetric ratio to simulate typical PRP preparations used in the clinical setting. For example, the PL condition in this study is representative of a clinical PRP that is approximately 14 times more concentrated than baseline (Table III). All experimental media conditions contained 20% PL, 78% α-MEM, 1% GlutaMAX, and 1% penicillin-streptomycin by volume. Culture medium containing 1% FBS, 20% PPP, and 20% FBS supplemented with 1 ng/ml recombinant human basic fibroblast growth factor (hBFGF; Gold Biotechnology, Inc., St. Louis, Missouri) were used as negative, PPP, and positive controls, respectively. All culture media preparations were filter sterilized using 0.22 µm syringe filters (EMD Millipore, Billerica, Massachusetts).

Proliferation assay. Tenocytes were plated at a density of 1000 cells/cm² within collagen-coated, multi-well plates (Corning), using expansion medium. Following an initial 24-hour attachment period, the cultures were starved with serum-free medium for an additional 24 hours, after which the experimental and control media conditions were added. Tenocyte cultures were maintained in a humidified incubator at 37°C and 5% CO₂ for 72 or 120 hours. After each timepoint, cell proliferation was qualitatively assessed by phase-contrast microscopy (EVOS FL; Thermo Fisher Scientific), and the genomic DNA was quantified using a fluorometric-based DNA assay in accordance with the manufacturer’s recommendations (Quant-iT PicoGreen; Thermo Fisher Scientific).

Migration assay. Tenocytes were plated at a density of 30 000 cells/cm² within specialized inserts (Ibidi GmBH, Martinsried, Germany) that were previously adhered to the culture surfaces of multi-well plates (Corning). Cells were grown in expansion medium until confluence, and reproducible cell-free gaps, approximately 500 µm in width, were created upon careful removal of the inserts. The tenocyte cultures were washed once with phosphate-buffered saline (PBS) prior to addition of experimental media conditions. Phase-contrast images of the gap region were acquired (EVOS FL; Thermo Fisher Scientific) immediately following insert removal, and after 24, 32, and 48 hours of culture in experimental media. The gap area was measured using imaging software (Image; NIH, Bethesda, Maryland) and the percentage of gap closure was calculated by the equation ((A₀ - Aₜ)/A₀) * 100, where A₀ is the initial gap area and Aₜ is the area remaining at the timepoint of interest.

Table III. Simulated clinical platelet-rich plasma (PRP) concentrations

| Experimental condition | Representative clinical PRP concentration |
|------------------------|------------------------------------------|
| Platelet lysate (PL)   | 14x                                      |
| 1/2 PL                 | 7x                                       |
| 1/4 PL                 | 3.5x                                     |
| 1/8 PL                 | 1.75x                                    |
| 1/16 PL                | 0.9x                                     |

A high-resolution image was acquired (Q-View Imager; Quansys Biosciences) and the protein concentration within each PL sample was determined by comparing chemiluminescent intensities with that of an eight-point standard curve (Q-view; Quansys Biosciences).

Culture of human tenocytes. Cryopreserved human tenocytes (n = 3) from the Achilles, patellar, and palmaris tendons of a 61-year-old man, a 65-year-old woman, and an 81-year-old man, respectively, were purchased from a commercial supplier (Zen-Bio Inc., Research Triangle Park, North Carolina). Upon thawing, tenocytes were plated in collagen-I coated tissue culture flasks (Corning Inc., Corning, New York) using expansion medium consisting of 88% minimal essential medium-alpha (α-MEM; Lonza, Basel, Switzerland), 10% foetal bovine serum (FBS; Corning Inc.), 1% GlutaMAX (Thermo Fisher Scientific, Waltham, Massachusetts), and 1% penicillin-streptomycin (Thermo Fisher Scientific) by volume. Cultures were maintained in a humidified incubator at 37°C and 5% CO₂, with periodic media changes until ~80% confluent, at which point the tenocytes were trypsinized and replated for proliferation and migration assays. Tenocytes utilized for this study were not expanded beyond the fifth passage.
Protein levels increase with PL concentration. Quantification of multiple anabolic growth factors, anti-catabolic tissue inhibitors, and pro-inflammatory cytokines are shown in Figure 1. Protein levels were confirmed to increase concomitantly with PL concentration, with higher levels typically presenting within the PLs from aged donors. Anabolic growth factors measured included bFGF, platelet-derived growth factor BB (PDGFB-BB), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF); anti-catabolic tissue inhibitors, e) tissue inhibitor of metalloproteinase 1 (TIMP1) and f) tissue inhibitor of metalloproteinase 2 (TIMP2); and pro-inflammatory cytokines, g) interleukin (IL)-8 and h) tumour necrosis factor alpha (TNF-α). *Samples with protein levels below the lower limit of detection.
growth factor (VEGF). With a more than ten-fold increase between the lowest and highest PL concentrations in both donor groups, protein levels of PDGF-BB and VEGF changed the most (Figs 1c and 1d). Of the two antici-catabolic tissue inhibitors quantified, tissue inhibitor of metalloproteinase 1 (TIMP1) was more affected than tissue inhibitor of metalloproteinase 2 (TIMP2) with respect to changes in PL concentration (Figs 1e and 1f). While detected at lower overall levels, the pro-inflammatory cytokines interleukin 8 (IL-8) and tumour necrosis factor alpha (TNF-α) also went up with PL concentration (Figs 1g and 1h).

Aged PLs promote tenocyte proliferation in a concentration-dependent manner. Increasingly concentrated PLs stimulated tenocyte proliferation differently depending on donor age, as shown in Figure 2. Tenocytes were maintained in cell culture medium containing PLs for 72 or 120 hours, at which point tenocyte proliferation was assessed by quantifying DNA (Fig. 2a). After 72 hours of culture, tenocyte growth was similar to, or better than, that of the positive control condition. Significant differences between higher PL concentrations and PPP were only observed in the aged donor group (Fig. 2b). After 120 hours of culture, PLs from the aged donors clearly promoted cell growth in a dose-dependent manner, with significant increases observed between the highest and lowest PL concentrations. In contrast, fewer significant differences were observed between tenocytes cultured in PLs from the young donor group, with only the midrange PLs resulting in significantly greater proliferation than PPP (Fig. 2c). Although the highest PL concentration from the young donors resulted in lower tenocyte proliferation relative to the midrange PLs, the culture medium within this condition tended to undergo sporadic hydrogel formation, which likely affected the results (Supplementary Figure a).
PLATELET LYSATES FROM AGED DONORS PROMOTE HUMAN TENOCYTE PROLIFERATION AND MIGRATION IN A CONCENTRATION-DEPENDENT MANNER

37

Aged PLs promote tenocyte migration in a concentration-dependent manner. Tenocyte migration in PLs from aged donors was markedly different depending on the PL concentration, as shown in Figure 4. Representative phase-contrast images demonstrate an absence of cellular migration when tenocytes are cultured in PPP. However, as the PL concentration is increased, the extent of tenocyte migration is noticeably improved (Fig. 4a). Quantification of the cell-free area revealed significant differences between different PL concentrations after 36 and 48 hours of culture (Fig. 4b). By comparison, Figure 5 demonstrates PL from young donors to promote tenocyte migration largely independent of concentration. Significant differences in tenocyte migration were measured between the PLs and PPP, but not between any of the PL concentrations investigated (Fig. 5b). Similar to the proliferation results, tenocyte migration was weakly promoted in PPP from young, but not aged, donors.

Discussion
Determining the optimal platelet concentration to facilitate PRP-induced tendon repair in an ageing patient population remains a clinical challenge. In the present study, PLs, prepared from concentrated PRP and pooled based on donor age, were added to tenocyte cultures to determine the effects on cell behaviour. Quantification of the PL preparations revealed greater platelet-derived protein levels with increasing PL concentration and, generally, greater protein levels were found in PLs from the aged donor group. Platelet-derived growth factor BB and VEGF, two growth factors involved in the early inflammatory and reparative stages of tendon healing, were most impacted by changes in PL concentration. Of the two anti-catabolic tissue inhibitors quantified, TIMP2 levels were less dependent on PL concentration, in accordance with previously published results. Low, but detectable, concentrations of the pro-inflammatory cytokines IL-8 and TNF-α were measured, and their presence could signify leucocyte contamination. However, other investigations have detected similar concentrations of these two cytokines in PRP with less than 0.3% of the initial white blood cells remaining.

Tenocyte proliferation and migration were found to increase significantly with platelet-derived protein levels when cultured in pooled PLs derived from aged, but not young, donors. The results seen with the aged PL largely support the findings of Jo et al, in which tenocyte proliferation is stimulated by PRP in a dose-dependent manner without detrimental effects at higher platelet concentrations. The general trend of improved tenocyte proliferation and migration with increased PL concentrations suggests that higher PRP concentrations (up to 14 ×) may be more beneficial than lower PRP concentrations for promoting tendon repair in an ageing patient population. Indeed, a recent clinical study has proposed increasing the platelet concentration of PRP for treating tendinopathies among the elderly patient population. This patient population receives PRP therapy for musculoskeletal injuries with increased frequency and has an increased prevalence of tendon-related injuries.

Interestingly, PPP from young donors was found to promote tenocyte proliferation and migration weakly, whereas PPP from their older counterparts did not.

Characterization of tenocyte proliferation following culture with increasing concentrations of pooled platelet lysates (PLs) by phase contrast microscopy. a) Tenocytes cultured with negative (1% foetal bovine serum (FBS)) and positive (20% FBS + basic fibroblast growth factor (bFGF)) experimental control conditions after 120 hours. b) Tenocytes cultured with pooled PL (or platelet-poor plasma (PPP)) from different donor age groups after 120 hours. Representative images shown are from a single tenocyte donor (81-year-old male, palmaris tendon). Scale bar = 500 µm.
Emerging data demonstrating that increased volumes of PPP inhibit angiogenic responses in vitro, including cell proliferation and migration, suggests that optimal activity is obtained by reducing the presence of inhibitory plasma proteins.\textsuperscript{24} Cell culture studies investigating thrombospondin-1 (TSP1) and TIMP2 have shown these plasma proteins to reduce cell growth.\textsuperscript{25,26} In the present study, quantified TIMP2 levels were found to be almost two times greater than those in aged PPP, consistent with the observed lack of tenocyte growth and migration. Moreover, the dose-response in tenocyte behaviour with increasing PL concentration may result from shifting the balance between inhibitory factors in the plasma in favour of mitogenic factors within platelets. Although several studies have concluded that high platelet concentrations are inhibitory to cell growth, they often rely upon
dosing protocols that increase platelet concentration by adjusting the volumetric ratio of PRP to cell culture medium, thereby increasing the presence of inhibitory plasma proteins and potentially confounding the results. Additional investigations are necessary to better understand how the interplay between different platelet concentrations, the presence of plasma proteins, and patient age impacts tendon healing.

A renewed approach towards improving our understanding of PRP through basic scientific research can help to safeguard patient safety and further optimize PRP formulations for specific indications. However, our study
included limitations one must consider when interpreting the results. Due to difficulties encountered when adding pure PRP to cell cultures, lysing via successive freeze and thaw steps was chosen as the optimal method to isolate the platelet-derived protein content, as recommended by others. Given that an in vitro culture model was used to measure the effects of concentrated PRPs on tendon cell growth and migration from a small number of blood and tenocyte donors, we acknowledge that the cellular microenvironment lacked several physiologically relevant characteristics, and that our study is limited in size.

In conclusion, this study reveals that higher PL concentrations promote increased tenocyte proliferation and migration when derived from ageing, but not young, donors. These results suggest that increasing the platelet concentration within PRP may be a useful biological strategy for helping tendon regeneration in an ageing patient population.

Supplementary material

A table showing representative platelet, white blood cell (WBC), and red blood cell (RBC) counts in platelet-rich plasma (PRP); a table showing representative platelet count in PRP and concentrated PRP; and representative images of tenocytes from a single tenocyte donor.

References

1. Nourissat G, Houard X, Sellam J, Duprez D, Berenbaum F. Use of autologous growth factors in aging tendon and chronic tendinopathy. Front Biosci 2013;5:911–921.
2. Andia I, Martin JL, Maffulli N. Advances with platelet rich plasma therapies for tendon regeneration. Expert Opin Biol Ther 2018;18:389–398.
3. Amable PR, Carias RBV, Teixeira MVT, et al. Platelet-rich plasma therapy for regeneration of bone: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther 2013;4:67.
4. Kannus P, Paavolu M, Józsa L. Aging and degeneration of tendons. In: Maffulli N, Renström P, eds. Tendon regeneration. London: Springer-Verlag, 2005:25–31.
5. Docheva D, Müller SA, Majewski M, Evans CH. Biologics for tendon repair. Adv Drug Deliv Rev 2015;84:222–239.
6. Chen X, Jones IA, Park C, Vangsness CT Jr. The efficacy of platelet-rich plasma on tendon and ligament healing: a systematic review and meta-analysis with bias assessment. Am J Sports Med 2018;46:2020–2032.
7. de Vos R-J, Windt J, Weir A. Strong evidence against platelet-rich plasma effectiveness for helping tendon regeneration in an ageing patient: a systematic review. Front Aging Neurosci 2016;8:1513.
8. Nourissat G, Houard X, Sellam J, Duprez D, Berenbaum F. Use of autologous growth factors in aging tendon and chronic tendinopathy. Front Biosci 2013;5:911–921.
9. Andia I, Martin JL, Maffulli N. Advances with platelet rich plasma therapies for tendon regeneration. Expert Opin Biol Ther 2018;18:389–398.
10. Amable PR, Carias RBV, Teixeira MVT, et al. Platelet-rich plasma therapy for regeneration of bone: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther 2013;4:67.
11. Docheva D, Müller SA, Majewski M, Evans CH. Biologics for tendon repair. Adv Drug Deliv Rev 2015;84:222–239.
12. Graziuani F, Ivanovski S, Ceil S, et al. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 2006;17:212–219.
13. Cho HS, Song IH, Park S-Y, et al. Individual variation in growth factor concentrations in platelet-rich plasma and its influence on human mesenchymal stem cells. Korean J Lab Med 2011;31:212–218.
14. Giusti I, D’Ascenzo S, Mancò A, et al. Platelet concentration in platelet-rich plasma affects tenocyte behavior in vitro. BioMed Res Int 2014;2014:630870.
15. Jo CH, Kim JE, Yoon KS, Shin S. Platelet-rich plasma stimulates cell proliferation and enhances matrix gene expression and synthesis in tenocytes from human rotator cuff tendons with degenerative tears. Am J Sports Med 2012;40:1035–1045.
16. Araki J, Jona M, Eto H, et al. Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods 2012;18:176–185.
17. Wilson BH, Cole BJ, Goodale MB, Fortier LA. Short-term storage of platelet-rich plasma at room temperature does not affect growth factor or catabolic cytokine concentration. Am J Orthop 2018;47.
18. Strandberg G, Sellberg F, Sommar P, et al. Standardizing the freeze-thaw preparation of growth factors from platelet lyate. Transfusion 2017;57:1058–1065.
19. Murate T, Yamashita K, Isogai C, et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryocytes: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br J Haematol 1997;99:181–189.
20. Salini V, Vanni D, Pantalone A, Abate M. Platelet rich plasma therapy in non-insertional achilles tendinopathy: the efficacy is reduced in 60-years old people compared to young and middle-age individuals. Front Aging Neurosci 2015;7:228.
21. Zhang JY, Fabricant PD, Ishmael CR, et al. Utilization of platelet-rich plasma for musculoskeletal injuries: an analysis of current treatment trends in the United States. Orthop J Sports Med 2016;4:2325967116676241.
22. Albers IS, Zwerver J, Diercks RL, Dekker JH, Van den Ackere-Scheek I. Incidence and prevalence of lower extremity tendinopathy in a Dutch general practice population: a cross sectional study. BMC Musculoskelet Disord 2016;17:16.
23. Tashjian RZ. Epidemiology, natural history, and indications for treatment of rotator cuff tears. Clin Sports Med 2012;31:589–604.
24. Eulain J, Mena HA, Meiss RP, et al. An optimised protocol for platelet-rich plasma preparation to improve its angiogenic and regenerative properties. Sci Rep 2018;8:1513.
25. Seo D-W, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2002;114:171–180.
26. Hsu CW, Yuan K, Tseng C-C. The negative effect of platelet-rich plasma on the growth of human cells is associated with secreted thrombospondin-1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;107:185–192.
27. Murray IR, LaPrade RF. Platelet-rich plasma: renewed scientific understanding must guide appropriate use. Bone Joint Res 2016;5:92-94.
28. Spanoudes K, Gaspar D, Pandit A, Zeugolis DI. The biophysical, biophysical, and biological toolbox for tenogenic phenotype maintenance in vitro. Trends Biotechnol 2014;32:474–482.

Author contribution

D. R. Berger: Collected, analyzed, and interpreted the data. Wrote and edited the manuscript.
C. J. Centeno: Designed the study, edited the manuscript.
N. J. Steinmetz: Designed and supervised the study. Wrote and edited the manuscript.

Funding statement

The author or one or more of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article.

ICMJE COI statement

D. Berger reports the use of laboratory equipment provided by Regenexx, LLC, as well as funding from John C. Malone in the form of a gift in support of the Interventional Orthopedic Foundation’s initiatives in regenerative medicine. N. J. Steinmetz reports consultancy fees, lecture payments, payment for the development of educational presentations, and payment for contributing to the creation of the manuscript, all from Interventional Orthopedic Foundation.

© 2019 Author(s) et al. This is an open-access article distributed under the terms of the Creative Commons Attributions licence (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited.